The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Open accessAbstract
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin-proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands, notably for von Hippel-Lindau (VHL) and cereblon (CRBN), revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity. A first wave of PROTAC drugs are now undergoing clinical development in cancer, and the field is seeking to extend the repertoire of chemistries that allow hijacking new E3 ligases to improve the scope of targeted protein degradation.Here, we briefly review how traditional E3 ligase ligands were discovered, and then outline approaches and ligands that have been recently used to discover new E3 ligases for PROTACs. We will then take an outlook at current and future strategies undertaken that invoke either target-based screening or phenotypic-based approaches, including the use of DNA-encoded libraries (DELs), display technologies and cyclic peptides, smaller molecular glue degraders, and covalent warhead ligands. These approaches are ripe for expanding the chemical space of PROTACs and usher in the advent of other emerging bifunctional modalities of proximity-based pharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Self-citationLysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Self-citationLessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
Single-particle cryo-EM at atomic resolution
Nakane, T., Kotecha, A., Sente, A., McMullan, G., Masiulis, S., Brown, P. M. G. E., Grigoras, I. T., Malinauskaite, L., Malinauskas, T., Miehling, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2829-0 · Cited by 868
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
HIF and c-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and Proliferation
Gordan, J. D., Thompson, C. B., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.006 · Cited by 803
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G., Elledge, S. J., Conaway, R. C., et al. (1999) · Science · doi:10.1126/science.284.5414.657 · Cited by 781
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
Min, J.-H., Yang, H., Ivan, M., Gertler, F., Kaelin, W. G., & Pavletich, N. P. (2002) · Science · doi:10.1126/science.1073440 · Cited by 765
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Heinis, C., Rutherford, T., Freund, S., & Winter, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.184 · Cited by 743
Cyclic peptide therapeutics: past, present and future
Zorzi, A., Deyle, K., & Heinis, C. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.02.006 · Cited by 737
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., & Arimoto, H. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.009 · Cited by 675
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
DNA-encoded chemistry: enabling the deeper sampling of chemical space
Goodnow, R. A., Dumelin, C. E., & Keefe, A. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.213 · Cited by 621
Structure of a β-TrCP1-Skp1-β-Catenin Complex
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., & Pavletich, N. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00234-x · Cited by 612
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Self-citationBAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Self-citationAllele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
Li, Z., Wang, C., Wang, Z., Zhu, C., Li, J., Sha, T., Ma, L., Gao, C., Yang, Y., Sun, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1722-1 · Cited by 551
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Maher, E. R., & Kaelin, W. G. (1997) · Medicine · doi:10.1097/00005792-199711000-00001 · Cited by 528
Redox-based reagents for chemoselective methionine bioconjugation
Lin, S., Yang, X., Jia, S., Weeks, A. M., Hornsby, M., Lee, P. S., Nichiporuk, R. V., Iavarone, A. T., Wells, J. A., Toste, F. D., et al. (2017) · Science · doi:10.1126/science.aal3316 · Cited by 513
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 487
Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W., & Pavletich, N. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.022 · Cited by 460
TRIM24 links a non-canonical histone signature to breast cancer
Tsai, W.-W., Wang, Z., Yiu, T. T., Akdemir, K. C., Xia, W., Winter, S., Tsai, C.-Y., Shi, X., Schwarzer, D., Plunkett, W., et al. (2010) · Nature · doi:10.1038/nature09542 · Cited by 434
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0304-8 · Cited by 432
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404
Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Self-citationSelective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function
James, L. C., Keeble, A. H., Khan, Z., Rhodes, D. A., & Trowsdale, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609174104 · Cited by 386
Rational discovery of molecular glue degraders via scalable chemical profiling
Mayor-Ruiz, C., Bauer, S., Brand, M., Kozicka, Z., Siklos, M., Imrichova, H., Kaltheuner, I. H., Hahn, E., Seiler, K., Koren, A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0594-x · Cited by 369
Tello, D., Balsa, E., Acosta-Iborra, B., Fuertes-Yebra, E., Elorza, A., Ordóñez, Á., Corral-Escariz, M., Soro, I., López-Bernardo, E., Perales-Clemente, E., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.008 · Cited by 368
Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348
Yamagishi, Y., Shoji, I., Miyagawa, S., Kawakami, T., Katoh, T., Goto, Y., & Suga, H. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.09.013 · Cited by 346
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336
Self-citationWard, C. C., Kleinman, J. I., Brittain, S. M., Lee, P. S., Chung, C. Y. S., Kim, K., Petri, Y., Thomas, J. R., Tallarico, J. A., McKenna, J. M., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01083 · Cited by 336
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W., & Pavletich, N. P. (2003) · Molecules and Cells · Cited by 333
Davies, T. G., Wixted, W. E., Coyle, J. E., Griffiths-Jones, C., Hearn, K., McMenamin, R., Norton, D., Rich, S. J., Richardson, C., Saxty, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00228 · Cited by 322
Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312
Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Self-citationRNA Display Methods for the Discovery of Bioactive Macrocycles
Huang, Y., Wiedmann, M. M., & Suga, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00430 · Cited by 298
A Poised Chromatin Platform for TGF-β Access to Master Regulators
Xi, Q., Wang, Z., Zaromytidou, A.-I., Zhang, X. H.-F., Chow-Tsang, L.-F., Liu, J. X., Kim, H., Barlas, A., Manova-Todorova, K., Kaartinen, V., et al. (2011) · Cell · doi:10.1016/j.cell.2011.11.032 · Cited by 285
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281
Iminoboronates: A New Strategy for Reversible Protein Modification
Cal, P. M. S. D., Vicente, J. B., Pires, E., Coelho, A. V., Veiros, L. F., Cordeiro, C., & Gois, P. M. P. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303436y · Cited by 275
Mdm2: keeping p53 under control
Piette, J., Neel, H., & Maréchal, V. (1997) · Oncogene · doi:10.1038/sj.onc.1201432 · Cited by 266
Multispecific drugs herald a new era of biopharmaceutical innovation
Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
Cleasby, A., Yon, J., Day, P. J., Richardson, C., Tickle, I. J., Williams, P. A., Callahan, J. F., Carr, R., Concha, N., Kerns, J. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098896 · Cited by 258
Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Sackton, K. L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T. B., Meaders, J., Pfaff, K. L., Sigoillot, F., Yu, H., et al. (2014) · Nature · doi:10.1038/nature13660 · Cited by 257
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
Bussiere, D. E., Xie, L., Srinivas, H., Shu, W., Burke, A., Be, C., Zhao, J., Godbole, A., King, D., Karki, R. G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0411-6 · Cited by 257
Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones
Maianti, J. P., McFedries, A., Foda, Z. H., Kleiner, R. E., Du, X. Q., Leissring, M. A., Tang, W.-J., Charron, M. J., Seeliger, M. A., Saghatelian, A., et al. (2014) · Nature · doi:10.1038/nature13297 · Cited by 254
EMT: A new vision of hypoxia promoting cancer progression
Jiang, J., Tang, Y.-L., & Liang, X.-H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.8.15274 · Cited by 253
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245
Self-citationOhoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240
Marcotte, D., Zeng, W., Hus, J.-C., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A., Enyedy, I., Cuervo, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.019 · Cited by 239
Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L., Epemolu, O., Shimamura, S., Bantscheff, M., Grandi, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms13312 · Cited by 239
Self-citationBulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
Self-citationAn N-end rule pathway that recognizes proline and destroys gluconeogenic enzymes
Chen, S.-J., Wu, X., Wadas, B., Oh, J.-H., & Varshavsky, A. (2017) · Science · doi:10.1126/science.aal3655 · Cited by 225
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells
Semenza, G. L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.08.001 · Cited by 217
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., Xu, T., Wang, M., Yang, C.-Y., Chinnaswamy, K., Stuckey, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01393 · Cited by 208
Honda, T., Rounds, B. V., Gribble, G. W., Suh, N., Wang, Y., & Sporn, M. B. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00479-x · Cited by 204
Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction
Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.013 · Cited by 200
Phosphorylation-Inducing Chimeric Small Molecules
Siriwardena, S. U., Munkanatta Godage, D. N. P., Shoba, V. M., Lai, S., Shi, M., Wu, P., Chaudhary, S. K., Schreiber, S. L., & Choudhary, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c05537 · Cited by 190
Van Molle, I., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.015 · Cited by 188
Self-citationKonopleva, M., Tsao, T., Ruvolo, P., Stiouf, I., Estrov, Z., Leysath, C. E., Zhao, S., Harris, D., Chang, S., Jackson, C. E., et al. (2002) · Blood · doi:10.1182/blood.v99.1.326 · Cited by 188
Cardote, T. A. F., & Ciulli, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201500450 · Cited by 186
Self-citationNaylor, M. R., Bockus, A. T., Blanco, M.-J., & Lokey, R. S. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.012 · Cited by 185
Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Macrocycles as protein–protein interaction inhibitors
Dougherty, P. G., Qian, Z., & Pei, D. (2017) · Biochemical Journal · doi:10.1042/bcj20160619 · Cited by 176
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Zhao, Q., Lan, T., Su, S., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c8cc07813k · Cited by 176
Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation
Sekine, K., Takubo, K., Kikuchi, R., Nishimoto, M., Kitagawa, M., Abe, F., Nishikawa, K., Tsuruo, T., & Naito, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709525200 · Cited by 173
Lim, S., Khoo, R., Peh, K. M., Teo, J., Chang, S. C., Ng, S., Beilhartz, G. L., Melnyk, R. A., Johannes, C. W., Brown, C. J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920251117 · Cited by 170
Petrylak, D. P., Gao, X., Vogelzang, N. J., Garfield, M. H., Taylor, I., Dougan Moore, M., Peck, R. A., & Burris, H. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3500 · Cited by 169
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.048 · Cited by 169
Self-citationPalmer, W. S., Poncet-Montange, G., Liu, G., Petrocchi, A., Reyna, N., Subramanian, G., Theroff, J., Yau, A., Kost-Alimova, M., Bardenhagen, J. P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00405 · Cited by 168
Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 165
Self-citationTarget 2035: probing the human proteome
Carter, A. J., Kraemer, O., Zwick, M., Mueller-Fahrnow, A., Arrowsmith, C. H., & Edwards, A. M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.020 · Cited by 165
Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex
Cardote, T. A. F., Gadd, M. S., & Ciulli, A. (2017) · Structure · doi:10.1016/j.str.2017.04.009 · Cited by 162
Self-citationHomo-PROTACs for the Chemical Knockdown of Cereblon
Steinebach, C., Lindner, S., Udeshi, N. D., Mani, D. R., Kehm, H., Köpff, S., Carr, S. A., Gütschow, M., & Krönke, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00693 · Cited by 162
SNIPERs—Hijacking IAP activity to induce protein degradation
Naito, M., Ohoka, N., & Shibata, N. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.002 · Cited by 162
Zhuang, C., Narayanapillai, S. C., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 159
Bardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 154
Nrf2 activation through the inhibition of Keap1–Nrf2 protein–protein interaction
Lee, S., & Hu, L. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02539-y · Cited by 150
Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study
Yamazoe, S., Tom, J., Fu, Y., Wu, W., Zeng, L., Sun, C., Liu, Q., Lin, J. M., Lin, K., Fairbrother, W. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01167 · Cited by 148
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Phage Display: Simple Evolution in a Petri Dish (Nobel Lecture)
Smith, G. P. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201908308 · Cited by 131
Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
Ohoka, N., Tsuji, G., Shoda, T., Fujisato, T., Kurihara, M., Demizu, Y., & Naito, M. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00704 · Cited by 123
2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles
Zambaldo, C., Vinogradova, E. V., Qi, X., Iaconelli, J., Suciu, R. M., Koh, M., Senkane, K., Chadwick, S. R., Sanchez, B. B., Chen, J. S., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02721 · Cited by 121
Okuhira, K., Ohoka, N., Sai, K., Nishimaki-Mogami, T., Itoh, Y., Ishikawa, M., Hashimoto, Y., & Naito, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.019 · Cited by 118
Molecular basis of GID4-mediated recognition of degrons for the Pro/N-end rule pathway
Dong, C., Zhang, H., Li, L., Tempel, W., Loppnau, P., & Min, J. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0036-1 · Cited by 111
Development and Characterization of a Wee1 Kinase Degrader
Li, Z., Pinch, B. J., Olson, C. M., Donovan, K. A., Nowak, R. P., Mills, C. E., Scott, D. A., Doctor, Z. M., Eleuteri, N. A., Chung, M., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.10.013 · Cited by 111
Structural analysis of human Cdc20 supports multisite degron recognition by APC/C
Tian, W., Li, B., Warrington, R. T., Tomchick, D. R., Yu, H., & Luo, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213438109 · Cited by 108
Takimoto, R., MacLachlan, T. K., Dicker, D. T., Niitsu, Y., Mori, T., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.65 · Cited by 104
Shimokawa, K., Shibata, N., Sameshima, T., Miyamoto, N., Ujikawa, O., Nara, H., Ohoka, N., Hattori, T., Cho, N., & Naito, M. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00247 · Cited by 104
PROTAC-mediated crosstalk between E3 ligases
Steinebach, C., Kehm, H., Lindner, S., Vu, L. P., Köpff, S., Mármol, Á. L., Weiler, C., Wagner, K. G., Reichenzeller, M., Krönke, J., et al. (2019) · Chemical Communications · doi:10.1039/c8cc09541h · Cited by 104
Heightman, T. D., Callahan, J. F., Chiarparin, E., Coyle, J. E., Griffiths-Jones, C., Lakdawala, A. S., McMenamin, R. L., Mortenson, P. N., Norton, D., Peakman, T. M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00279 · Cited by 103
Bensimon, A., Pizzagalli, M. D., Kartnig, F., Dvorak, V., Essletzbichler, P., Winter, G. E., & Superti-Furga, G. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.04.003 · Cited by 102
In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15
Li, L., Mi, D., Pei, H., Duan, Q., Wang, X., Zhou, W., Jin, J., Li, D., Liu, M., & Chen, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00245-0 · Cited by 102
Bifunctional chemical probes inducing protein–protein interactions
Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100
Self-citationRecognition of the Diglycine C-End Degron by CRL2KLHDC2 Ubiquitin Ligase
Rusnac, D.-V., Lin, H.-C., Canzani, D., Tien, K. X., Hinds, T. R., Tsue, A. F., Bush, M. F., Yen, H.-C. S., & Zheng, N. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.021 · Cited by 93
Chan, A. I., McGregor, L. M., Jain, T., & Liu, D. R. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04880 · Cited by 92
Chessari, G., Buck, I. M., Day, J. E. H., Day, P. J., Iqbal, A., Johnson, C. N., Lewis, E. J., Martins, V., Miller, D., Reader, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00706 · Cited by 90
De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains
Nawatha, M., Rogers, J. M., Bonn, S. M., Livneh, I., Lemma, B. E., Mali, S. M., Vamisetti, G. B., Sun, H. H., Bercovich, B., Huang, Y., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0278-x · Cited by 85
Cappadocia, L., Mascle, X. H., Bourdeau, V., Tremblay‐Belzile, S., Chaker-Margot, M., Lussier-Price, M., Wada, J., Sakaguchi, K., Aubry, M., Ferbeyre, G., et al. (2014) · Structure · doi:10.1016/j.str.2014.10.015 · Cited by 78
Zadjali, F., Pike, A. C. W., Vesterlund, M., Sun, J., Wu, C., Li, S. S. ‐., Rönnstrand, L., Knapp, S., Bullock, A. N., & Flores‐Morales, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.173526 · Cited by 77
Strategies for transitioning macrocyclic peptides to cell-permeable drug leads
Walport, L. J., Obexer, R., & Suga, H. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.07.007 · Cited by 77
Schumacher, F.-R., Sorrell, F. J., Alessi, D. R., Bullock, A. N., & Kurz, T. (2014) · Biochemical Journal · doi:10.1042/bj20140153 · Cited by 76
Zambaldo, C., Daguer, J.-P., Saarbach, J., Barluenga, S., & Winssinger, N. (2016) · MedChemComm · doi:10.1039/c6md00242k · Cited by 75
Kim, K. B., Lotan, R., Yue, P., Sporn, M. B., Suh, N., Gribble, G. W., Honda, T., Wu, G. S., Hong, W. K., & Sun, S. Y. (2002) · Molecular Cancer Therapeutics · Cited by 75
Structural Basis of Selective Ubiquitination of TRF1 by SCFFbx4
Zeng, Z., Wang, W., Yang, Y., Chen, Y., Yang, X., Diehl, J. A., Liu, X., & Lei, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.01.007 · Cited by 73
Tamanini, E., Buck, I. M., Chessari, G., Chiarparin, E., Day, J. E. H., Frederickson, M., Griffiths-Jones, C. M., Hearn, K., Heightman, T. D., Iqbal, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01877 · Cited by 72
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide–Peptoid Hybrid CXCR7 Modulators
Boehm, M., Beaumont, K. C., Jones, R., Kalgutkar, A. S. S., Zhang, L., Atkinson, K. A., Bai, G., Brown, J. A., Eng, H. F., Goetz, G. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01028 · Cited by 72
Mita, M., Kelly, K. R., Mita, A., Ricart, A. D., Romero, O., Tolcher, A., Hook, L., Okereke, C., Krivelevich, I., Rossignol, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0010 · Cited by 71
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Filippakopoulos, P., Low, A., Sharpe, T., Uppenberg, J., Yao, S., Kuang, Z., Savitsky, P. A., Lewis, R. S., Nicholson, S. E., Norton, R. S., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.06.017 · Cited by 67
Jiang, C., Zhuang, C., Zhu, K., Zhang, J., Muehlmann, L. A., Longo, J. P. F., Azevedo, R. B., Zhang, W., Meng, N., & Zhang, H. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1461856 · Cited by 62
Yokoi, A., Kuromitsu, J., Kawai, T., Nagasu, T., Sugi, N. H., Yoshimatsu, K., Yoshino, H., & Owa, T. (2002) · PubMed · Cited by 61
Sun, H.-P., Jiang, Z., Zhang, M.-Y., Lu, M., Yang, T., Pan, Y., Huang, H., Zhang, X., & You, Q. (2013) · MedChemComm · doi:10.1039/c3md00240c · Cited by 59
Li, Y., Jin, K., Bunker, E. N., Zhang, X., Luo, X., Liu, X., & Hao, B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708677115 · Cited by 58
Ohoka, N., Ujikawa, O., Shimokawa, K., Sameshima, T., Shibata, N., Hattori, T., Nara, H., Cho, N., & Naito, M. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00567 · Cited by 57
Liu, Y., Lau, J. L., Li, W., Tempel, W., Li, L., Dong, A., Narula, A., Qin, S., & Min, J. (2015) · Biochemical Journal · doi:10.1042/bj20150830 · Cited by 56
Johnson, C. N., Ahn, J. S., Buck, I. M., Chiarparin, E., Day, J. E. H., Hopkins, A., Howard, S., Lewis, E. J., Martins, V., Millemaggi, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00900 · Cited by 56
Owa, T., Okauchi, T., Yoshimatsu, K., Sugi, N. H., Ozawa, Y., Nagasu, T., Koyanagi, N., Okabe, T., Kitoh, K., & Yoshino, H. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00219-5 · Cited by 54
Lucas, X., Molle, I. V., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00842 · Cited by 48
Self-citationStructural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase
Kung, W.-W., Ramachandran, S., Makukhin, N., Bruno, E., & Ciulli, A. (2019) · Nature Communications · doi:10.1038/s41467-019-10190-4 · Cited by 43
Self-citationProof-of-Concept with PROTACs in Prostate Cancer
(2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2020-054 · Cited by 42
FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system
Yalla, K. C., Elliott, C., Day, J. P., Findlay, J., Barratt, S., Hughes, Z. A., Wilson, L., Whiteley, E. L., Popiolek, M., Li, Y., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.138 · Cited by 40
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K., Lee, D.-H., Park, S., Jo, S.-H., Ku, B., Park, S. G., Park, B. C., Jeon, Y. U., Ahn, S., Kang, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56177-5 · Cited by 39
Structural Basis for Recruitment of DAPK1 to the KLHL20 E3 Ligase
Chen, Z., Picaud, S., Filippakopoulos, P., D'Angiolella, V., & Bullock, A. N. (2019) · Structure · doi:10.1016/j.str.2019.06.005 · Cited by 37
Non-competitive cyclic peptides for targeting enzyme–substrate complexes
McAllister, T. E., Yeh, T., Abboud, M. I., Leung, I. K. H., Hookway, E. S., King, O. N. F., Bhushan, B., Williams, S. T., Hopkinson, R. J., Münzel, M., et al. (2018) · Chemical Science · doi:10.1039/c8sc00286j · Cited by 34
Ostertag, M. S., Messias, A. C., Sattler, M., & Popowicz, G. M. (2018) · Structure · doi:10.1016/j.str.2018.10.005 · Cited by 32
Biophysical Studies on Interactions and Assembly of Full-size E3 Ubiquitin Ligase
Bulatov, E., Martin, E. M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616664 · Cited by 30
Self-citationNor, S. M., & Haron, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1037-9_243 · Cited by 29
Bound Waters Mediate Binding of Diverse Substrates to a Ubiquitin Ligase
Muñoz-Escobar, J., Matta‐Camacho, E., Cho, C., Kozlov, G., & Gehring, K. (2017) · Structure · doi:10.1016/j.str.2017.03.004 · Cited by 26
The polar warhead of a TRIM 24 bromodomain inhibitor rearranges a water‐mediated interaction network
Liu, J., Li, F., Bao, H., Jiang, Y., Zhang, S., Ma, R., Gao, J., Wu, J., & Ruan, K. (2017) · FEBS Journal · doi:10.1111/febs.14041 · Cited by 23
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00159-9 · Cited by 23
Ostertag, M. S., Hutwelker, W., Plettenburg, O., Sattler, M., & Popowicz, G. M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.017 · Cited by 21
Sadek, M. M., Barlow, Ν., Leung, E. W. W., Williams‐Noonan, B. J., Yap, B. K., Shariff, F. M., Caradoc-Davies, T. T., Nicholson, S. E., Chalmers, D. K., Thompson, P. E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00561 · Cited by 21
Monovalent protein-degraders – Insights and future perspectives
Cornella‐Taracido, I., & García-Echeverría, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127202 · Cited by 20
You, T., Wang, Y., Li, K., Zhang, D., Wei, H., Luo, Y., Li, H., Lu, Y., Su, X., & Kuang, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.122 · Cited by 19
New class of molecule targets proteins outside cells for degradation
Whitworth, C., & Ciulli, A. (2020) · Nature · doi:10.1038/d41586-020-02211-w · Cited by 17
Self-citationBaur, M., Gneist, M., Owa, T., & Dittrich, C. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282ef4189 · Cited by 16
Bekaii‐Saab, T., Mortazavi, A., Hicks, L. G., Zalupski, M. M., Pelley, R. J., Chan, K. K., & Kraut, E. H. (2006) · Investigational New Drugs · doi:10.1007/s10637-005-4827-3 · Cited by 15
Zhao, B., Payne, W. G., Sai, J., Lu, Z., Olejniczak, E. T., & Fesik, S. W. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b01073 · Cited by 14
SPRY domain-containing SOCS box protein 2 complexed with WDINNN(BAL) cyclic peptide inhibitor
Law, R. H. P., Caradoc-Davies, T. T., & Norton, R. S. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6dn5/pdb · Cited by 9
Exploring DCAF15 for reprogrammable targeted protein degradationPreprint
Coomar, S., & Gillingham, D. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/542506 · Cited by 7
Brand, M., & Winter, G. E. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0312-8 · Cited by 6
Cited by
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
An overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Metadata
- Authors
- Ishida, T., & Ciulli, A.
- Venue
- SLAS Discovery
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 26
- Issue
- 4
- Pages
- 484-502
- ISSN
- 2472-5552 (ISSN-L)
- OpenAlex
- W3095840616
- Cited by
- 380
- References
- 172
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.